Page last updated: 2024-09-02

ecteinascidin 743 and carboplatin

ecteinascidin 743 has been researched along with carboplatin in 8 studies

Compound Research Comparison

Studies
(ecteinascidin 743)
Trials
(ecteinascidin 743)
Recent Studies (post-2010)
(ecteinascidin 743)
Studies
(carboplatin)
Trials
(carboplatin)
Recent Studies (post-2010) (carboplatin)
66010240412,8954,0015,244

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Barlow, C; Florez, A; Garcia, M; Judson, I; Kaye, SB; Lebedinsky, C; Magem, M; Montes, A; Pardo, B; Salazar, R; Vidal, L1
González, A1
Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G1
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U1
Bonetti, A; Giuliani, J1
Baldoni, A; Biagioli, E; Colombo, N; D'Incalci, M; Farina, G; Ferrero, A; Fossati, R; Frezzini, S; Galli, F; Gerardi, C; Lissoni, AA; Negri, E; Palluzzi, E; Pesenti Gritti, A; Poli, D; Rubino, D; Rulli, E; Scambia, G; Tognon, G; Torri, V; Zaccarelli, E1
González-Martín, A; Lorusso, D; Ray-Coquard, I1
Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P1

Reviews

1 review(s) available for ecteinascidin 743 and carboplatin

ArticleYear
Increasing the chances for platinum-sensitive ovarian cancer patients.
    Future oncology (London, England), 2013, Volume: 9, Issue:12 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2013

Trials

4 trial(s) available for ecteinascidin 743 and carboplatin

ArticleYear
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dioxoles; England; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spain; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult

2012
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome

2017
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    British journal of cancer, 2019, Volume: 121, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Progression-Free Survival; Survival Rate; Trabectedin

2019
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
    British journal of cancer, 2023, Volume: 128, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin

2023

Other Studies

3 other study(ies) available for ecteinascidin 743 and carboplatin

ArticleYear
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
    Oncotarget, 2016, May-03, Volume: 7, Issue:18

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin

2017
Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
    Future oncology (London, England), 2021, Volume: 17, Issue:3s

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Trabectedin

2021